97 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
17 Aug 20
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer
8:34am
are advancing multiple therapeutic candidates within our innovative pipeline of epilepsy treatments, so it is timely to add Chris’ strengths and skillset … of highly differentiated, deep science. With one of the most innovative neuroscience pipelines in the biotech industry today, we have the potential
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
21 Jun 22
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA
7:03am
development. One of Xenon’s key goals is to deliver innovative medicines that improve the lives of patients with epilepsy. Supported by the strong data … Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
14 Jan 21
Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021
8:05am
as a premier neuroscience company focused on developing and delivering innovative medicines to improve the health of patients with epilepsy and other … to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
7 Aug 18
Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
4:51pm
development of our innovative therapies to address epilepsy and other indications, and allows us to evaluate and potentially add new programs into our … .
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
21 May 20
Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
4:05pm
pipeline of innovative epilepsy treatments, and we are fortunate to have the cash runway to support our business objectives.”
Dr. Pimstone continued … to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology
8-K
EX-99.1
0h7ah3dq540vq1au
9 Nov 23
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
4:06pm
8-K
EX-99.1
5n2kejs6
12 Jan 22
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
8:04am
8-K
EX-99.1
eaov5nwu
23 Aug 21
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer
8:33am
8-K
EX-99.1
1zhh fpri95c
11 Sep 18
Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program
12:00am
8-K
EX-99.1
mrzg3w16pb1mwf5fvm5
7 Nov 22
Other Events
4:06pm
8-K
EX-99.1
be8a8pekvxkpjeh002
8 Sep 21
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
8:32am
8-K
EX-99.1
o88e9vcorxj3q pn98er
8 Aug 23
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
4:07pm
8-K
EX-99.1
1jxtzuxh
15 May 18
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference
7:23am
8-K
EX-99.1
1kn fkv71e
27 Nov 23
Other Events
7:03am
8-K
EX-99.2
1oej zok4st7
15 May 18
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference
7:23am
8-K
EX-99.1
4apvjjqniq
7 May 19
Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
4:40pm
8-K
EX-99.1
chctagumtgm68w25
2 Dec 19
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
7:52am
8-K
EX-99.1
y1utb5yyetze dobr8u
6 Aug 19
Xenon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
4:39pm
8-K
EX-99.1
ryn6unbo4
9 Aug 23
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
u2lsgp ndajs
29 Feb 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm